[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gram-negative-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gram-negative-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100566120","pkpd-analysis-of-ceftazidimeavibactam-or-cefiderocol-with-or-without-fosfomycin-for-the-treatment-of-difficult-to-treat-gram-negative-infections-100566120",false,"NCT06651047","PK\u002FPD Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","Pharmacokinetic\u002FPharmacodynamic Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","PACCOF","Inclusion Criteria:\n\n* Patients with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ\u002FAVI alone, CEF alone, CAZ\u002FAVI plus FOS, or CEF plus FOS (any age)\n* Signature of the informed consent (for pediatric patients: parents or guardians able to provide consent)\n\nExclusion Criteria:\n\n* Premature newborns\n* Polymicrobial\u002Fmixed infections with the exception of cases with multiple Gram-negative bacteria susceptible to study drugs\n* Continuous renal replacement therapy (CRRT) applications\n\nInclusion Criteria for Healthy Volunteer Subjects:\n\n* Age ≥18 years\n* Signature of the informed consent\n\nExclusion Criteria for Healthy Volunteer Subjects:\n\n\\- Any known clinically relevant health problems",true,"ALL",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime\u002Favibactam (CAZ\u002FAVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime\u002Favibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.",[25,26],"Gram Negative Infection","Antimicrobial Resistance (AMR)",[28,29,30,31,32,33],"Gram-negative infection","Ceftazidime\u002FAvibactam","Cefiderocol","Fosfomycin","Pharmacokinetics\u002FPharmacodynamics targets","Carbapenem-resistant Enterobacterales (CRE)","RECRUITING","2024-10-18",{"date":37,"type":38},"2024-10-21","ACTUAL",{"date":40,"type":38},"2024-07-09",{"date":42,"type":21},"2025-09-30",{"name":44,"class":45},"University of Bologna","OTHER",11]